Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review
This article was originally published in The Gray Sheet
Executive Summary
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded
You may also be interested in...
Vysis PathVysion Cleared For Herceptin Labeling; Is Early Detection Next?
Genentech's Herceptin revised labeling allows use of Abbott/Vysis' PathVysion FISH assay to select drug treatment, but declines to support the assay's utility for the general population
Vysis PathVysion Cleared For Herceptin Labeling; Is Early Detection Next?
Genentech's Herceptin revised labeling allows use of Abbott/Vysis' PathVysion FISH assay to select drug treatment, but declines to support the assay's utility for the general population
Abbott/Vysis PathVysion HER-2 Test Labeling Cleared To Carry Herceptin
Vysis will file an amendment to its PathVysion PMA to include retrospective outcome data from Genentech comparing the fluorescence in situ hybridization (FISH) test with immunohistochemistry (IHC) in its product labeling